Boston Scientific Announces Results For First Quarter 2021
News provided by
Share this article
Share this article
MARLBOROUGH, Mass., April 28, 2021 /PRNewswire/ Boston Scientific Corporation (NYSE: BSX) generated net sales of $2.752 billion during the first quarter of 2021. This represents growth of 8.2 percent on a reported basis, 5.6 percent on an operational
1 basis and 5.9 percent on an organic
2 basis, all compared to the prior year period. The company reported GAAP net income available to common stockholders of $327 million or $0.23 per share (EPS), compared to GAAP net income of $11 million or $0.01 per share a year ago, and achieved adjusted EPS of $0.37 for the period, compared to $0.28 a year ago.
Boston Scientific Announces Results For Fourth Quarter And Full Year 2020
News provided by
Share this article
Share this article
MARLBOROUGH, Mass., Feb. 3, 2021 /PRNewswire/ Boston Scientific Corporation (NYSE: BSX) generated net sales of $2.708 billion during the fourth quarter of 2020. This represents a decline of (6.8) percent on a reported basis, (8.3) percent on an operational
1 basis and (8.0) percent on an organic
2 basis, all compared to the prior year period. Included within organic results is a negative 370 basis point impact associated with the conversion of U.S. WATCHMAN™ customers to a consignment inventory model and transition to the next-generation WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device. The company reported GAAP net income available to common stockholders of $138 million or $0.10 per share (EPS), compared to GAAP net income of $3.996 billion or $2.83 per share a year ago and achieved adjusted EPS of $0.23 for the period, compared to $0.
/PRNewswire/ Boston Scientific Corporation (NYSE: BSX) generated net sales, based upon preliminary unaudited financial information, of approximately $2.71.